SciVision Biotech Inc. (1786.TW)
TWD 96.3
(-0.82%)
TWD 96.3
(-0.82%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 199.63 Million TWD | 23.83% |
| 2022 | 176.22 Million TWD | 41.83% |
| 2021 | 124.24 Million TWD | -23.26% |
| 2020 | 161.9 Million TWD | 15.09% |
| 2019 | 140.67 Million TWD | 74.41% |
| 2018 | 80.66 Million TWD | 200.29% |
| 2017 | 26.86 Million TWD | 203.34% |
| 2016 | -25.99 Million TWD | -155.3% |
| 2015 | 47 Million TWD | 312.42% |
| 2014 | -22.12 Million TWD | -170.48% |
| 2013 | 31.39 Million TWD | -38.01% |
| 2012 | 50.64 Million TWD | 16.51% |
| 2011 | 43.46 Million TWD | 444.27% |
| 2010 | -12.62 Million TWD | 75.22% |
| 2009 | -50.95 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 66.76 Million TWD | 30.34% |
| 2024 Q2 | 65.28 Million TWD | -2.18% |
| 2023 Q1 | 44.06 Million TWD | 13.26% |
| 2023 FY | 218.21 Million TWD | 23.83% |
| 2023 Q4 | 51.22 Million TWD | -31.13% |
| 2023 Q3 | 74.37 Million TWD | 53.21% |
| 2023 Q2 | 48.54 Million TWD | 10.16% |
| 2022 FY | 176.22 Million TWD | 41.83% |
| 2022 Q4 | 38.9 Million TWD | -28.85% |
| 2022 Q3 | 54.68 Million TWD | -2.93% |
| 2022 Q2 | 56.33 Million TWD | 114.18% |
| 2022 Q1 | 26.3 Million TWD | -22.22% |
| 2021 FY | 124.24 Million TWD | -23.26% |
| 2021 Q1 | 33.23 Million TWD | -25.79% |
| 2021 Q2 | 31.11 Million TWD | -6.38% |
| 2021 Q3 | 25.72 Million TWD | -17.32% |
| 2021 Q4 | 33.81 Million TWD | 31.45% |
| 2020 FY | 161.9 Million TWD | 15.09% |
| 2020 Q1 | 40.47 Million TWD | -13.17% |
| 2020 Q2 | 23.98 Million TWD | -40.75% |
| 2020 Q3 | 37.38 Million TWD | 55.89% |
| 2020 Q4 | 44.78 Million TWD | 19.79% |
| 2019 Q2 | 30.76 Million TWD | 7.12% |
| 2019 FY | 140.67 Million TWD | 74.41% |
| 2019 Q4 | 46.61 Million TWD | 65.99% |
| 2019 Q3 | 28.08 Million TWD | -8.7% |
| 2019 Q1 | 28.71 Million TWD | -3.52% |
| 2018 Q2 | 662 Thousand TWD | -98.34% |
| 2018 FY | 80.66 Million TWD | 200.29% |
| 2018 Q3 | 10.3 Million TWD | 1456.95% |
| 2018 Q4 | 29.76 Million TWD | 188.8% |
| 2018 Q1 | 39.92 Million TWD | 76.48% |
| 2017 Q3 | 3.1 Million TWD | -31.43% |
| 2017 FY | 26.86 Million TWD | 203.34% |
| 2017 Q2 | 4.52 Million TWD | 408.19% |
| 2017 Q1 | 891 Thousand TWD | -93.68% |
| 2017 Q4 | 22.62 Million TWD | 628.6% |
| 2016 Q2 | 2.12 Million TWD | 27.04% |
| 2016 Q3 | 9.92 Million TWD | 366.21% |
| 2016 Q4 | 14.08 Million TWD | 41.99% |
| 2016 FY | -25.99 Million TWD | -155.3% |
| 2016 Q1 | 1.67 Million TWD | -57.74% |
| 2015 Q2 | 6.55 Million TWD | -51.85% |
| 2015 Q4 | 3.96 Million TWD | -75.23% |
| 2015 FY | 47 Million TWD | 312.42% |
| 2015 Q1 | 13.62 Million TWD | 148.83% |
| 2015 Q3 | 16 Million TWD | 144.04% |
| 2014 Q2 | -503 Thousand TWD | 83.89% |
| 2014 FY | -22.12 Million TWD | -170.48% |
| 2014 Q4 | -27.89 Million TWD | -628.38% |
| 2014 Q3 | -3.83 Million TWD | -661.43% |
| 2014 Q1 | -3.12 Million TWD | -154.43% |
| 2013 Q2 | 8.43 Million TWD | 90.28% |
| 2013 Q4 | 5.73 Million TWD | -48.76% |
| 2013 FY | 31.39 Million TWD | -38.01% |
| 2013 Q1 | 4.43 Million TWD | -82.97% |
| 2013 Q3 | 11.19 Million TWD | 32.69% |
| 2012 Q4 | 26.04 Million TWD | 86.94% |
| 2012 Q3 | 13.93 Million TWD | 94.64% |
| 2012 Q1 | 3.87 Million TWD | -67.14% |
| 2012 Q2 | 7.15 Million TWD | 84.75% |
| 2012 FY | 50.64 Million TWD | 16.51% |
| 2011 Q3 | 12.18 Million TWD | 0.0% |
| 2011 FY | 43.46 Million TWD | 444.27% |
| 2011 Q4 | 11.79 Million TWD | -3.26% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -12.62 Million TWD | 75.22% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | -50.95 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 259.91 Million TWD | 23.19% |
| Maxigen Biotech Inc. | 149.85 Million TWD | -33.225% |
| Bionime Corporation | -13.33 Million TWD | 1596.649% |
| Pegavision Corporation | 1.98 Billion TWD | 89.923% |
| Visco Vision Inc. | 334.7 Million TWD | 40.354% |